Urolithin A is a compound your gut bacteria produce when you consume foods rich in ellagitannins — pomegranates, certain berries, and walnuts among them. It has attracted scientific attention primarily for its ability to activate mitophagy, the cellular process that identifies and clears out worn-out mitochondria and makes room for healthier replacements. As interest in supplementation has grown, one of the most common practical questions is straightforward: how much urolithin A per day is actually supported by evidence?
The honest answer is that human research on this compound is still early-stage. A small number of clinical trials have tested specific doses for safety and biological effect, but large-scale, long-term dose-response studies are lacking. This article walks through what those studies found, where the evidence runs out, and what that means for anyone considering urolithin A supplementation.
Key Takeaways
- The primary human clinical trial tested 500 mg and 1000 mg daily doses and found both safe and biologically active, with the higher dose producing a more pronounced mitochondrial gene expression response [3].
- Urolithin A activates mitophagy — the cellular process that clears damaged mitochondria — meaning effective dosing is tied to reaching concentrations that meaningfully engage this pathway.
- Food-derived urolithin A is highly variable: gut microbiome composition determines how much ellagitannins are converted, making direct supplementation the more consistent delivery route.
- Dose-dependent relationships between ellagitannin intake and urolithin metabolite levels have been confirmed in dietary research [2], supporting the biological plausibility of dose-response effects.
- Long-term dose-response data in humans is lacking; current evidence supports short-term safety at 500–1000 mg but cannot establish an optimal dose for extended use.
Why Dosage Matters: The Mitophagy Mechanism
Mitochondria — the organelles that generate energy inside your cells — accumulate damage over time. Cells have a quality-control process called mitophagy that tags dysfunctional mitochondria for removal and recycling. When this process slows down, damaged mitochondria linger, contributing to the energy deficits and cellular dysfunction associated with aging.
Urolithin A appears to work primarily by upregulating this mitophagy process. At effective concentrations, it activates molecular pathways that improve the tagging and clearance of damaged mitochondria, which may in turn support the renewal of the mitochondrial pool and overall cellular energy capacity. The dose you take determines whether urolithin A reaches the tissue concentrations needed to meaningfully activate these pathways — which is why the question of dosage is biologically substantive, not just a marketing decision.
Understanding this mechanism also clarifies the limits of current evidence: researchers can measure whether a dose activates mitophagy-related gene expression, but translating that into specific functional outcomes — like muscle strength, endurance, or long-term health markers — requires much larger and longer trials than have been completed to date.
The Key Human Clinical Trial: What Doses Were Tested?
The most directly relevant human data comes from a first-in-human study published in Nature Metabolism, which assessed urolithin A supplementation in healthy older adults across multiple dose levels, including 500 mg and 1000 mg per day over a four-week period [3]. Researchers measured safety, tolerability, and molecular markers of mitochondrial and cellular health, including gene expression related to mitophagy and mitochondrial biogenesis.
The study found that urolithin A was safe at all tested doses, with no serious adverse events reported [3]. Crucially, it also induced a molecular signature consistent with improved mitochondrial function — providing the first direct evidence in humans that oral urolithin A supplementation reaches tissues and activates the same biological pathways previously observed only in preclinical models [3]. This was a significant finding because it validated that the compound is orally bioavailable and biologically active at realistic supplement doses.
500 mg vs 1000 mg: Is There a Dose-Response Effect?
Within the range studied in [3], there was a signal suggesting that higher doses produced more pronounced molecular changes. The 1000 mg daily dose appeared to generate a stronger mitochondrial gene expression response than 500 mg. However, the study was not sized or designed to determine whether this molecular difference translates into meaningful differences in functional outcomes such as physical performance or metabolic health markers.
This dose-response relationship is consistent with findings from dietary ellagitannin research more broadly. A study using standardized black raspberry food products — which are rich in ellagitannin precursors that gut bacteria convert into urolithin metabolites — found dose-dependent increases in ellagitannin metabolites in participants consuming larger amounts, confirming that higher intake leads to proportionally greater urolithin-type metabolite production [2]. Whether the same linear relationship holds for direct urolithin A supplementation across a wider dose range in humans remains an open question.
In practical terms, the current evidence supports both 500 mg and 1000 mg as biologically active and safe doses, with the 1000 mg range showing a more robust molecular response in the available trial [3]. There is no published human data supporting doses substantially above this range.
Dietary Sources: Can Food Alone Provide Effective Amounts?
Urolithin A is not found pre-formed in food in meaningful quantities. It is produced by gut bacteria acting on ellagitannin precursors found in pomegranate, certain berries, walnuts, and some other plant foods. The amounts generated from food depend on what you eat, how consistently you eat it, and — critically — which gut microbes you carry.
Research on specific food sources confirms that dietary ellagitannins can reach urolithin-producing pathways. A study using watermelon juice enriched with pomegranate ellagitannins found measurable urolithin metabolites in participants and observed effects on metabolism during physical exercise [1]. More recently, a crossover clinical trial found that acid hydrolysis of jaboticaba peel and seed powder — a preparation that increases ellagitannin bioavailability — led to increased urolithin excretion in healthy participants [5]. These findings confirm food-derived ellagitannins can contribute to urolithin exposure, though amounts generated are generally lower and more variable than what is delivered by direct supplementation.
Mediterranean dietary patterns, which include polyphenol-rich foods such as pomegranate and berries among many other plant sources, have been associated with favorable cardiovascular markers in large epidemiological work [4]. Whether urolithin A specifically drives any part of that association, or whether it reflects the broader polyphenol portfolio, has not been established.
Individual Variation: Why One Dose Does Not Fit All
One of the most important factors in urolithin A biology is gut microbiome composition. The bacteria that convert dietary ellagitannins into urolithin A are not universally present, and research has found that a substantial portion of people produce little to no urolithin A from ellagitannin-rich foods — even after consuming significant amounts of pomegranate or berry products. This makes food-based urolithin A delivery highly unpredictable across individuals.
Direct supplementation with urolithin A bypasses this gut conversion step entirely, delivering the active compound without dependence on microbiome composition. This is a genuine practical advantage for people who are non-producers or low producers from diet. However, individual differences in intestinal absorption, hepatic metabolism, and tissue uptake still exist, and the human trials conducted so far have been in relatively small, defined populations — limiting confident generalizations across diverse groups.
What the Evidence Supports — and Where It Ends
The clearest evidence-based statement that can be made about urolithin A dosage is this: 500 mg to 1000 mg per day has been tested in adult humans, found to be safe over a four-week period, and shown to activate molecular markers of mitochondrial health, with a more pronounced response at the higher dose [3]. Commercial supplements are generally formulated within this studied range.
What the evidence cannot currently support: optimal dosing for specific populations (older adults vs younger, athletes vs sedentary individuals), long-term safety beyond short study periods, or dose thresholds tied to specific functional outcomes. No regulatory body has established a recommended daily intake. The current evidence base is promising but genuinely preliminary, and it is worth holding that framing when evaluating supplement marketing claims.
🛒 Where to Buy Urolithin A
- Timeline Mitopure SoftgelsClinically studied
softgels, 500 mg/day — The clinically studied form (Amazentis); used in the human trials. - DoNotAge Pure Urolithin A
capsules, 250-500 mg — Popular longevity-brand generic, third-party tested. - ProHealth Longevity Urolithin A
capsules, 500 mg — Longevity-focused brand, often higher dose. - Double Wood Urolithin A
capsules, 250-500 mg — Budget-friendly, widely available, COA on request.
As an Amazon Associate we earn from qualifying purchases. Prices and availability vary; verify dose and third-party testing before buying.
A Note on the Evidence
The human clinical evidence on urolithin A dosage is limited in scale and duration; existing trials are small and measured biomarkers rather than long-term health outcomes, so no firm dosage recommendations can be made. Anyone with underlying health conditions, those who are pregnant or breastfeeding, or those taking medications should consult a qualified healthcare provider before starting any new supplement.
Frequently Asked Questions
What is the recommended dose of urolithin A per day?
There is no officially established recommended dose. The most relevant human trial tested 500 mg and 1000 mg daily and found both safe and biologically active over four weeks, with 1000 mg showing a more pronounced mitochondrial gene expression response [3]. Most commercial supplements are formulated within this studied range.
Is 500 mg of urolithin A per day enough to have an effect?
In the key human clinical trial, 500 mg per day produced measurable molecular changes consistent with mitophagy activation and was well tolerated [3]. Whether 500 mg is sufficient for a given individual’s goals cannot be answered definitively by the current evidence, but it falls within the range where biological activity has been demonstrated.
Can you get enough urolithin A from eating pomegranate?
Pomegranate is rich in ellagitannins, which gut bacteria convert into urolithin A. Research combining pomegranate ellagitannins with other sources found measurable urolithin metabolites and effects on exercise metabolism [1]. However, the amount produced depends heavily on your gut microbiome, and many people do not carry bacteria efficient enough to generate amounts comparable to direct supplementation.
Is urolithin A safe to take daily?
The published first-in-human trial found urolithin A supplementation at 500–1000 mg per day to be safe and well tolerated over a four-week study period, with no serious adverse events [3]. Long-term safety data beyond short trial periods is limited, so extended use warrants appropriate caution and ideally medical guidance.
Does taking more urolithin A produce a stronger effect?
Within the doses studied, there is a signal that higher doses produce more pronounced changes in mitochondrial gene expression [3]. Research on ellagitannin precursors also confirms dose-dependent increases in urolithin metabolites with higher dietary intake [2]. Whether this translates to meaningfully better functional outcomes at 1000 mg versus 500 mg has not been demonstrated in human trials.
Why do some people seem to respond more than others?
When consuming dietary sources of ellagitannins, gut microbiome composition is the dominant variable — people without the relevant bacteria produce little or no urolithin A from food, regardless of how much they eat. Direct supplementation bypasses this conversion step. Even so, individual differences in absorption and metabolism mean response to supplementation is unlikely to be uniform, though the research to characterize this variability in humans is still limited.
References
- Martínez-Sánchez A et al. Consumption of Watermelon Juice Enriched in l-Citrulline and Pomegranate Ellagitannins Enhanced Metabolism during Physical Exercise. Journal of agricultural and food chemistry (2017). PMID 28513179
- Roberts KM et al. Dose-Dependent Increases in Ellagitannin Metabolites as Biomarkers of Intake in Humans Consuming Standardized Black Raspberry Food Products Designed for Clinical Trials. Molecular nutrition & food research (2020). PMID 32112501
- Andreux PA et al. The mitophagy activator urolithin A is safe and induces a molecular signature of improved mitochondrial and cellular health in humans. Nature metabolism (2019). PMID 32694802
- Domínguez-López I et al. Urinary polyphenol signature of the Mediterranean diet is associated with lower cardiovascular disease risk: the PREDIMED trial. BMC medicine (2025). PMID 41408634
- Bizarelo R et al. Acid hydrolysis of jaboticaba (Myrciaria jaboticaba) peel and seed powder increases urolithin excretion in a cross-over clinical trial with normoweight subjects. Food & function (2026). PMID 42023516
